US EditionFDA approves Moderna’s RSV vaccine for seniors, the company’s second-ever product
- "FDA approved Moderna's respiratory syncytial virus vaccine for those 60 and older, marking the company's second product launch."
- "Moderna's RSV vaccine shows 83.7% efficacy in preventing lower respiratory tract disease based on clinical trial data involving 37,000 adults in 22 countries."
- "Moderna's longer-term analysis indicates continued protection nearly nine months post-vaccination with no serious safety concerns reported.
17 Articles
17 Articles
Moderna wins second product approval with RSV vaccine
Moderna’s respiratory syncytial virus vaccine for older adults received U.S. regulatory approval, the company said Friday, marking the first time a messenger RNA vaccine has been approved for a disease other than COVID-19.
US FDA approves Moderna’s RSV vaccine, its second marketed product
By Patrick Wingrove (Reuters) – The U.S. Food and Drug Administration has approved Moderna’s respiratory syncytial virus (RSV) vaccine, the company announced on Friday, giving it a shot at much-needed new revenue from a second product. Moderna’s vaccine was approved by the FDA for the prevention of RSV-associated lower respiratory tract disease in adults aged 60 or older. RSV, which produces symptoms similar to a cold but can be fatal for y…
US FDA approves Moderna's RSV vaccine, its second marketed product
The U.S. Food and Drug Administration has approved Moderna's respiratory syncytial virus (RSV) vaccine, the company announced on Friday, giving it a shot at much-needed new revenue from a second product.
Coverage Details
Bias Distribution
- 75% of the sources are Center
To view factuality data please Upgrade to Premium
